Johnson & Johnson (JNJ)
Health Care · Integrated Pharmaceuticals & Healthcare Products · NYSE
A diversified healthcare giant producing pharmaceuticals, medical devices, and consumer health products with a focus on innovation-driven therapeutic breakthroughs across oncology, immunology, infectious disease, and cardiovascular markets.
What Johnson & Johnson does
Johnson & Johnson is a diversified healthcare company that develops, manufactures, and sells pharmaceuticals, medical devices, diagnostics, and consumer health products globally. The company operates through multiple business segments focusing on therapeutic areas including oncology, immunology, infectious disease, cardiovascular health, and consumer wellness. J&J pursues growth through product innovation, clinical development, regulatory approvals, and strategic acquisitions, while navigating extensive regulatory oversight from the U.S. FDA and international counterparts.
Themes: ["Pharmaceutical innovation","Patent protection and intellectual property","FDA regulatory approval","Oncology","Immunology","Product liability and litigation","Healthcare pricing and reimbursement","Biosimilar competition","Clinical development","Global healthcare markets"]
Fundamentals
- Price$259.10 as of 2026-07-09 close
- Market cap$625.8B as of 2026-07-10
- 1-year return+65.8% as of 2026-07-09 close
- P/E29.74 as of 2026-07-10
- Net margin+21.8% as of 2026-07-10
- Gross margin+68.0% as of 2026-07-10
- ROE+26.3% as of 2026-07-10
- Debt / equity0.68 as of 2026-07-10
- Revenue growth (YoY)+7.9% as of 2026-07-10
- Revenue CAGR (3y)+6.2% SEC XBRL
- Beta0.23 as of 2026-07-10
Dividend: yield +2.1%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Patent expirations and biosimilar/generic competition threatening market exclusivity and revenue from key products","Significant ongoing product liability litigation (talc, pharmaceutical marketing practices) with potential for material settlements exceeding current accruals and reputational damage","Regulatory uncertainty including FDA approval delays, changing manufacturing standards, pricing/reimbursement restrictions, and government investigations creating compliance costs and potential debarment from government healthcare programs"]
Competitors & peers
- Pfizer
- Merck
- Roche
- Novartis
- AbbVie
- Eli Lilly
- Bristol Myers Squibb
- AstraZeneca
- Sanofi
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.